MCID: HYP020
MIFTS: 59

Hyperprolactinemia

Categories: Genetic diseases, Rare diseases, Endocrine diseases, Reproductive diseases, Metabolic diseases

Aliases & Classifications for Hyperprolactinemia

MalaCards integrated aliases for Hyperprolactinemia:

Name: Hyperprolactinemia 54 12 24 71 29 52 42 14 69
Chiari-Frommel Syndrome 12 50 42 69
Hprl 24 71
Familial Isolated Prolactin Receptor Deficiency 56
Pregnancy-Related a-G Syndrome 12
Familial Hyperprolactinemia 56
Hyperprolactinaemia 12

Characteristics:

Orphanet epidemiological data:

56
familial hyperprolactinemia
Inheritance: Autosomal dominant; Age of onset: Adult;

OMIM:

54
Inheritance:
autosomal dominant


HPO:

32
hyperprolactinemia:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Hyperprolactinemia

OMIM : 54
Hyperprolactinemia unrelated to pregnancy occurs in approximately 0.1 to 0.3% of the general population and may result in infertility, hypogonadism, and galactorrhea. Such nonphysiologic hyperprolactinemia is caused mainly by drugs or by tumors in the anterior pituitary gland, primarily prolactinomas (see 102200). However, 10 to 60% of patients with hyperprolactinemia who undergo MRI have normal findings (summary by Newey et al., 2013). (615555)

MalaCards based summary : Hyperprolactinemia, also known as chiari-frommel syndrome, is related to pityriasis rotunda and functioning pituitary adenoma, and has symptoms including osteoporosis, amenorrhea and infertility. An important gene associated with Hyperprolactinemia is PRLR (Prolactin Receptor), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Aripiprazole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and ovary, and related phenotypes are Increased shRNA abundance (Z-score > 2) and endocrine/exocrine gland

UniProtKB/Swiss-Prot : 71 Hyperprolactinemia: A disorder characterized by increased levels of prolactin in the blood not associated with gestation or the puerperium. HPRL may result in infertility, hypogonadism, and galactorrhea.

Disease Ontology : 12 An acquired metabolic disease that has material basis in the presence of abnormally-high levels of prolactin in the blood.

Related Diseases for Hyperprolactinemia

Diseases related to Hyperprolactinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 235)
id Related Disease Score Top Affiliating Genes
1 pityriasis rotunda 30.0 GH1 PRL
2 functioning pituitary adenoma 29.6 POMC SST
3 galactorrhoea-hyperprolactinaemia 10.8
4 mccune-albright syndrome, somatic, mosaic 10.8
5 genital dwarfism, turner type 10.7 PRL TRH
6 g6pc3 deficiency 10.7 GH1 PRL
7 rhinoscleroma 10.7 DRD2 PRL
8 glassy cell carcinoma of the cervix 10.7 GH1 PRL
9 adenomatoid tumor 10.6 GNRH1 PRL
10 ornithosis 10.6 DRD2 PRL
11 peroxisomal biogenesis disorders 10.6 DRD2 PRL
12 olfactory nerve neoplasm 10.6 POMC PRL
13 osteoclast-like giant cell neoplasm of the pancreas 10.6 POMC PRL
14 internal hemorrhoid 10.6 GNRH1 PRL
15 cholangiolocellular carcinoma 10.6 POMC TRH
16 lymphoma, gastric non hodgkins type 10.6 GH1 POMC
17 lipase deficiency, combined 10.5 GH1 IGF1
18 47,xyy syndrome 10.5 GH1 PRL
19 mixed glioma 10.5 GAL TRH
20 radioulnar synostosis with amegakaryocytic thrombocytopenia 1 10.5 GH1 IGF1
21 complement component 8 deficiency 10.4 GNRH1 IGF1
22 prostate leiomyoma 10.4 GNRH1 PRL PRLR
23 aromatase excess syndrome 10.4 GH1 GNRH1
24 growth hormone insensitivity, partial 10.4 GH1 IGF1
25 simple cryoglobulinemia 10.4 GH1 SST
26 febrile infection-related epilepsy syndrome 10.3 IGF1 POMC
27 plague 10.3 IGF1 PRL PRLR
28 vertebral artery occlusion 10.3 GNRH1 POMC PRL
29 acute female pelvic peritonitis 10.3 DRD2 POMC PRL
30 osseous heteroplasia, progressive 10.3 GH1 IGF1 PRL
31 retinitis pigmentosa 46 10.3 GNRH1 POMC PRL
32 sphingolipidosis 10.3 GNRH1 POMC PRL
33 aortic valve prolapse 10.3 GNRH1 PRL PRLR
34 uterine corpus adenocarcinofibroma 10.3 GNRH1 POMC PRL
35 spondylolysis 10.3 GNRH1 POMC PRL
36 ulcerative colitis 10.2 DRD2 IGF1
37 porokeratosis 10.2 GNRH1 IGF1 PRL
38 renal pelvis carcinoma 10.2 POMC SST
39 haverhill fever 10.2 GNRH1 IGF1 PRL
40 traumatic glaucoma 10.2 IGF1 POMC
41 ulcerative blepharitis 10.2 IGF1 POMC PRL
42 mononeuritis of upper limb and mononeuritis multiplex 10.2 IGF1 SST
43 immune system organ benign neoplasm 10.2 IGF1 POMC PRL
44 pseudopterygium 10.2 GNRH1 IGF1 PRL
45 precursor b lymphoblastic lymphoma/leukemia 10.2 GNRH1 IGF1 PRL
46 combined t cell and b cell immunodeficiency 10.1 GH1 PRL SST
47 simpson-golabi-behmel syndrome 10.1 DRD2 GNRH1
48 water-clear cell adenoma 10.1 DRD2 PRL SST
49 suppurative periapical periodontitis 10.1 DRD2 IGF1 POMC
50 hypodermyasis 10.1 GH1 POMC PTHLH

Graphical network of the top 20 diseases related to Hyperprolactinemia:



Diseases related to Hyperprolactinemia

Symptoms & Phenotypes for Hyperprolactinemia

Symptoms via clinical synopsis from OMIM:

54

Genitourinary- Internal Genitalia Female:
infertility (in some patients)
oligomenorrhea (in some patients)
menorrhagia (in some patients)

Endocrine Features:
elevated prolactin levels

Chest- Breasts:
galactorrhea (in some patients)


Clinical features from OMIM:

615555

Human phenotypes related to Hyperprolactinemia:

56 32 (show all 10)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 osteoporosis 56 32 occasional (7.5%) Occasional (29-5%) HP:0000939
2 amenorrhea 56 32 frequent (33%) Frequent (79-30%) HP:0000141
3 infertility 56 32 occasional (7.5%) Frequent (79-30%) HP:0000789
4 osteopenia 56 32 occasional (7.5%) Occasional (29-5%) HP:0000938
5 oligomenorrhea 56 32 occasional (7.5%) Very frequent (99-80%) HP:0000876
6 menorrhagia 56 32 occasional (7.5%) Occasional (29-5%) HP:0000132
7 galactorrhea 56 32 occasional (7.5%) Very frequent (99-80%) HP:0100829
8 female hypogonadism 56 32 occasional (7.5%) Occasional (29-5%) HP:0000134
9 hemorrhagic ovarian cyst 56 32 frequent (33%) Frequent (79-30%) HP:0012886
10 prolactin excess 32 HP:0000870

GenomeRNAi Phenotypes related to Hyperprolactinemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.74 POMC
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.74 IGF1 POMC GAL
3 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.74 IGF1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.74 GAL
5 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.74 POMC
6 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.74 IGF1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.74 GAL
8 Increased shRNA abundance (Z-score > 2) GR00366-A-158 9.74 GAL
9 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.74 IGF1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.74 IGF1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.74 IGF1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.74 IGF1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.74 GAL
14 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.74 IGF1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.74 IGF1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.74 GAL
17 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.74 IGF1 POMC
18 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.74 POMC
19 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.74 GAL
20 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.74 GAL
21 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.74 POMC
22 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.74 POMC
23 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.74 IGF1

MGI Mouse Phenotypes related to Hyperprolactinemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.13 DRD2 GAL GNRH1 IGF1 POMC PRL
2 homeostasis/metabolism MP:0005376 10.11 IGF1 POMC PRL PRLR PTHLH SST
3 behavior/neurological MP:0005386 10.06 DRD2 GAL POMC PRL PRLR PTHLH
4 growth/size/body region MP:0005378 10.06 DRD2 GAL GNRH1 IGF1 POMC PRLR
5 immune system MP:0005387 9.92 DRD2 GNRH1 IGF1 POMC PRL PTHLH
6 adipose tissue MP:0005375 9.88 DRD2 IGF1 POMC PRLR PTHLH
7 integument MP:0010771 9.86 DRD2 GAL GNRH1 IGF1 POMC PRL
8 nervous system MP:0003631 9.65 DRD2 GAL GNRH1 IGF1 POMC PRL
9 neoplasm MP:0002006 9.63 DRD2 GNRH1 IGF1 POMC PRL PRLR
10 reproductive system MP:0005389 9.23 IGF1 PRL PRLR PTHLH VIP DRD2

Drugs & Therapeutics for Hyperprolactinemia

Drugs for Hyperprolactinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
2
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2 51-61-6, 62-31-7 681
3
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
4
Cabergoline Approved Phase 4 81409-90-7 54746
5
Quinagolide Approved Phase 4 97805-50-0, 87056-78-8 105105
6
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
7
Amantadine Approved Phase 4 768-94-5 2130
8 Antipsychotic Agents Phase 4,Phase 3,Phase 2
9 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
10 Psychotropic Drugs Phase 4,Phase 3,Phase 2
11 Tranquilizing Agents Phase 4,Phase 3,Phase 2
12 Dopamine Agents Phase 4,Phase 3,Phase 1,Phase 2
13 Dopamine Antagonists Phase 4,Phase 3
14 Dopamine D2 Receptor Antagonists Phase 4
15 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2
16 Paliperidone Palmitate Phase 4
17
Serotonin Phase 4,Phase 3 50-67-9 5202
18 Serotonin 5-HT2 Receptor Antagonists Phase 4
19 Serotonin Agents Phase 4,Phase 3
20 Serotonin Antagonists Phase 4,Phase 3
21 Dopamine agonists Phase 4,Phase 3,Phase 1,Phase 2
22 Antiparkinson Agents Phase 4,Phase 3,Phase 1,Phase 2
23 Hormones Phase 4,Phase 3,Phase 2,Phase 1
24 Peripheral Nervous System Agents Phase 4,Phase 1,Phase 2
25 Estradiol 17 beta-cypionate Phase 4
26 Estradiol 3-benzoate Phase 4
27 Estradiol valerate Phase 4 979-32-8
28 Polyestradiol phosphate Phase 4
29 Analgesics Phase 4
30 Analgesics, Non-Narcotic Phase 4
31 Anti-Infective Agents Phase 4
32 Antiviral Agents Phase 4
33
Bromocriptine Approved, Investigational Phase 3 25614-03-3 31101
34 Hormone Antagonists Phase 3,Phase 2
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
36 Quetiapine Fumarate Phase 3 111974-72-2
37
Ropinirole Approved, Investigational Phase 1, Phase 2 91374-20-8, 91374-21-9 5095 497540
38 Licorice Approved, Nutraceutical Phase 2
39 Pharmaceutical Solutions Phase 2
40 Autonomic Agents Phase 1, Phase 2
41 Protective Agents Phase 1, Phase 2
42
Calcium Carbonate Approved 471-34-1
43
Levodopa Approved 59-92-7 6047
44
Bevacizumab Approved, Investigational 216974-75-3
45
Haloperidol Approved 52-86-8 3559
46
Olanzapine Approved, Investigational 132539-06-1 4585
47
Epinephrine Approved, Vet_approved 51-43-4 5816
48 Racepinephrine Approved
49
Ergocalciferol Approved, Nutraceutical 50-14-6 5280793
50
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2

Interventional clinical trials:

(show all 35)

id Name Status NCT ID Phase Drugs
1 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
2 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
3 High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone Unknown status NCT00539071 Phase 4 long-acting injectable risperidone;long acting injectable risperidone;long acting injectable risperidone
4 Aripiprazole and Prolactin Study Completed NCT01085383 Phase 4 Aripiprazole
5 Endometriosis Patients Undergoing Quinagolide Treatment Completed NCT00625950 Phase 4
6 Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients Completed NCT01957839 Phase 4 cabergoline treatment
7 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Phase 4 Cabergoline
8 The Luveris In Vitro Fertilization Trial Terminated NCT00889512 Phase 4 Luveris fixed dose;Luveris increasing dose
9 Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation Terminated NCT00975611 Phase 4 Amantadine Hydrochloride, USP;Amantadine Hydrochloride, USP;Placebo
10 Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine Unknown status NCT00315081 Phase 3 Bromocriptin
11 Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone Completed NCT00600756 Phase 3 Quetiapine XR;Risperidone
12 Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia Completed NCT01852331 Phase 2 PGD granules;Placebo
13 Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Recruiting NCT03038308 Phase 1, Phase 2 Ropinirole
14 Administration of Kisspeptin in Patients With Hyperprolactinemia Not yet recruiting NCT02956447 Phase 2 Kisspeptin 112-121;Gonadotropin Releasing Hormone (GnRH)
15 Administration of Kisspeptin to Subjects With Reproductive Disorders Recruiting NCT00914823 Phase 1 kisspeptin 112-121;GnRH
16 Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment Unknown status NCT00699530
17 Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia Unknown status NCT02013232 Aripiprazole
18 Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas. Unknown status NCT01143584 Cabergoline;cabergoline
19 Changes in Hyperprolactinemia Secondary to Antipsychotics After Switching to Quetiapine Completed NCT00952757
20 Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia Completed NCT00799383 Calcium and Vitamin D
21 Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia Completed NCT01338298 Aripiprazole;Placebo
22 Characterization of Macroprolactinemia Completed NCT00436111
23 The Relationship of PRL and Polycystic Ovary Syndrome (PCOS) in Taiwan's Women Completed NCT01117272
24 Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE) Completed NCT01270711 Study Drug
25 Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON Completed NCT02098668
26 The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events Completed NCT01052948
27 The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function Completed NCT00973557
28 Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy Completed NCT00399776
29 Comparison of Bone Mineral Density Changes During Tx With Risperidone or Aripiprazole in Adolescents Completed NCT00573716
30 Prevalence of Pregnancy in Polycystic Ovary Syndrome Completed NCT03157921
31 Insulin Resistance in Women With Prolactinoma Completed NCT00481299
32 Assessing Fertility Potential in Female Cancer Survivors Recruiting NCT01143844
33 Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly. Active, not recruiting NCT02092129
34 Pituitary Function and Spontaneous Intracranial Hypotension Active, not recruiting NCT02603549
35 TSH And AMH in Infertile Women Enrolling by invitation NCT02710175

Search NIH Clinical Center for Hyperprolactinemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: hyperprolactinemia

Genetic Tests for Hyperprolactinemia

Genetic tests related to Hyperprolactinemia:

id Genetic test Affiliating Genes
1 Hyperprolactinemia 29 24 PRLR

Anatomical Context for Hyperprolactinemia

MalaCards organs/tissues related to Hyperprolactinemia:

39
Pituitary, Bone, Ovary, Endothelial, Testes, Thyroid, Prostate

Publications for Hyperprolactinemia

Articles related to Hyperprolactinemia:

(show top 50) (show all 725)
id Title Authors Year
1
An Intact Dopamine Sensitivity in the Brain: A Necessity to Recover Hyperprolactinemia and Galactorrhea in a Female Hemodialysis Patient? ( 28791188 )
2017
2
Occurrence of hyperprolactinemia in children with subclinical hypothyroidism. ( 28529200 )
2017
3
Long-Term Follow-Up of Primary Medical Versus Surgical Treatment of Prolactinomas in Men: Effects on Hyperprolactinemia, Hypogonadism, and Bone Health. ( 27773859 )
2017
4
Re: Myocardial Recovery in Peripartum Cardiomyopathy after Hyperprolactinemia Treatment on Biventricular Assist Device. ( 28114195 )
2017
5
Resolution of dopamine agonist-resistant hyperprolactinemia by hysterectomy: a case report. ( 28925774 )
2017
6
Adjunctive metformin for antipsychotic-related hyperprolactinemia: A meta-analysis of randomized controlled trials. ( 28372526 )
2017
7
Re: Myocardial Recovery in Peripartum Cardiomyopathy After Hyperprolactinemia Treatment on Biventricular Assist Device. ( 28169846 )
2017
8
Pituitary gamma-aminobutyric acid receptor stimulation by carnitine may be a new strategy for antipsychotic-induced hyperprolactinemia. ( 28569425 )
2017
9
The central mechanism of risperidone-induced hyperprolactinemia. ( 28336493 )
2017
10
Paeoniflorin and liquiritin, two major constituents in Chinese herbal formulas used to treat hyperprolactinemia-associated disorders, inhibits prolactin secretion in prolactinoma cells by different mechanisms. ( 28396166 )
2017
11
Pulmonary Artery Occlusion and Mediastinal Fibrosis in a Patient on Dopamine Agonist Treatment for Hyperprolactinemia. ( 28775691 )
2017
12
Cooperative Synthesis of Dopamine in Rat Mediobasal Hypothalamus as a Compensatory Mechanism in Hyperprolactinemia. ( 28320278 )
2017
13
Serum prolactin revisited: parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia. ( 28236625 )
2017
14
Risperidone Induced Granulomatous Mastitis Secondary to Hyperprolactinemia in a Non-Pregnant Woman-A Rare Case Report in a Bipolar Disorder. ( 28273980 )
2017
15
Hyperprolactinemia and the Association with All-Cause Mortality and Cardiovascular Mortality. ( 28437810 )
2017
16
Idiopathic granulomatous mastitis associated with hyperprolactinemia: A nonoperative approach. ( 28845595 )
2017
17
Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. ( 28235557 )
2017
18
Effects of TNF-I+ on penile structure alteration in rats with hyperprolactinemia. ( 28763467 )
2017
19
Myocardial Recovery in Peripartum Cardiomyopathy After Hyperprolactinemia Treatment on BIVAD. ( 27748657 )
2017
20
Reply to: Hyperprolactinemia and Hirsutism in Patients without Polycystic Ovary Syndrome. ( 28761266 )
2017
21
Vasculogenic hyperprolactinemia: severe prolactin excess in association with internal carotid artery aneurysms. ( 28828544 )
2017
22
Time Course of Resolution of Hyperprolactinemia After Transsphenoidal Surgery Among Patients Presenting with Pituitary Stalk Compression. ( 27671881 )
2017
23
Therapeutic effects of Schisandra chinensis on the hyperprolactinemia in rat. ( 28259983 )
2017
24
Hyperprolactinemia with low dose of risperidone in a young female. ( 28558899 )
2017
25
Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. ( 28889207 )
2017
26
Pituitary Adenoma and Hyperprolactinemia Accompanied by Idiopathic Granulomatous Mastitis. ( 28321344 )
2017
27
Antipsychotic-induced hyperprolactinemia in Tourette syndrome. ( 28740637 )
2017
28
Cabergoline for hyperprolactinemia: getting to the heart of it. ( 28260205 )
2017
29
Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia. ( 27709470 )
2017
30
Menstrual Cycle Abnormalities in Patients with Prolactinoma and Drug-induced Hyperprolactinemia. ( 28670538 )
2017
31
Efficacy of Combined Cabergoline and Metformin Compared to Metformin Alone on Cycle Regularity in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: A Randomized Clinical Trial. ( 28867888 )
2017
32
Hyperprolactinemia Induced by Antipsychotics: From Diagnosis to Treatment Approach. ( 28440197 )
2017
33
The mechanism of selfheal extract in treating hyperprolactinemia. ( 28946556 )
2017
34
Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Women With Schizophrenia: A Randomized Controlled Trial. ( 27755159 )
2016
35
Pityriasis Rotunda and Hyperprolactinemia. ( 27006018 )
2016
36
The effect of metformin on prolactin levels in patients with drug-induced hyperprolactinemia. ( 26858210 )
2016
37
Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia. ( 28086010 )
2016
38
Pregabalin-induced hyperprolactinemia in a patient with fibromyalgia: A case report. ( 28275758 )
2016
39
Hyperprolactinemia Secondary to Pituitary Microadenoma versus Haloperidol-A Diagnostic Enigma: A Case Report and Brief Review. ( 27440143 )
2016
40
Prolactin gene polymorphism (-1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. ( 27776952 )
2016
41
Hyperprolactinemia induced by hCG leads to metabolic disturbances in female mice. ( 27154336 )
2016
42
Clinical profile of hyperprolactinemia. ( 27727650 )
2016
43
Chronic hyperprolactinemia evoked by disruption of lactotrope dopamine D2 receptors impacts on liver and adipocyte genes related to glucose and insulin balance. ( 27802964 )
2016
44
Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history. ( 27455388 )
2016
45
Prevalence and predictors of hyperprolactinemia in subclinical hypothyroidism. ( 27473607 )
2016
46
Profile of leptin, adiponectin, and body fat in patients with hyperprolactinemia: Response to treatment with cabergoline. ( 27042412 )
2016
47
18I^-Glycyrrhetinic Acid, a Novel Naturally Derived Agent, Suppresses Prolactin Hyperactivity and Reduces Antipsychotic-Induced Hyperprolactinemia in In Vitro and In Vivo Models. ( 27161375 )
2016
48
Rheumatoid Arthritis, Kartagener's Syndrome, and Hyperprolactinemia: Who Started It? ( 26904347 )
2016
49
Gynecomastia and Hyperprolactinemia Secondary to Advanced Allergic Fungal Rhinosinusitis in a Pediatric Patient. ( 26768883 )
2016
50
HYPERTHYROIDISM AND HYPERPROLACTINEMIA, IS THERE ANY ASSOCIATION? ( 27540882 )
2016

Variations for Hyperprolactinemia

UniProtKB/Swiss-Prot genetic disease variations for Hyperprolactinemia:

71
id Symbol AA change Variation ID SNP ID
1 PRLR p.His212Arg VAR_070895 rs398122522

ClinVar genetic disease variations for Hyperprolactinemia:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PRLR NM_001204316.1(PRLR): c.635A> G (p.His212Arg) single nucleotide variant Pathogenic rs398122522 GRCh37 Chromosome 5, 35070276: 35070276

Expression for Hyperprolactinemia

Search GEO for disease gene expression data for Hyperprolactinemia.

Pathways for Hyperprolactinemia

Pathways related to Hyperprolactinemia according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.78 DRD2 GAL GNRH1 IGF1 POMC PTHLH
2
Show member pathways
12.59 DRD2 GAL GH1 GNRH1 POMC PRL
3
Show member pathways
11.84 GH1 IGF1 POMC
4
Show member pathways
11.78 GH1 PRL PRLR
5 11.66 POMC PTHLH VIP
6 11.55 GH1 IGF1 PRLR
7 11.14 GH1 IGF1 PTHLH
8
Show member pathways
10.93 POMC TRH
9
Show member pathways
10.74 GH1 PRL PRLR

GO Terms for Hyperprolactinemia

Cellular components related to Hyperprolactinemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 GAL GH1 GNRH1 IGF1 POMC PTHLH
2 secretory granule GO:0030141 9.43 GAL POMC TRH
3 extracellular region GO:0005576 9.36 GAL GH1 GNRH1 IGF1 POMC PRL
4 endosome lumen GO:0031904 9.13 GH1 PRL PRLR

Biological processes related to Hyperprolactinemia according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 regulation of gene expression GO:0010468 9.67 GNRH1 IGF1 PTHLH
2 negative regulation of cell proliferation GO:0008285 9.55 DRD2 GAL GNRH1 PTHLH SST
3 response to ethanol GO:0045471 9.54 DRD2 GNRH1 TRH
4 response to steroid hormone GO:0048545 9.52 GNRH1 SST
5 positive regulation of multicellular organism growth GO:0040018 9.51 DRD2 GH1
6 adult walking behavior GO:0007628 9.48 DRD2 TRH
7 regulation of multicellular organism growth GO:0040014 9.46 IGF1 PRL
8 positive regulation of receptor internalization GO:0002092 9.43 DRD2 GH1
9 female pregnancy GO:0007565 9.43 GNRH1 PRL PTHLH
10 positive regulation of JAK-STAT cascade GO:0046427 9.4 GH1 PRL
11 cell-cell signaling GO:0007267 9.35 GNRH1 POMC PTHLH SST TRH
12 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.32 GH1 IGF1
13 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 8.8 GH1 PRL PRLR

Molecular functions related to Hyperprolactinemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.32 GAL GH1 GNRH1 IGF1 POMC PRL
2 prolactin receptor binding GO:0005148 9.16 GH1 PRL
3 neuropeptide hormone activity GO:0005184 8.96 GAL VIP

Sources for Hyperprolactinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....